Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. - Wikidata - awgldk - TriplyDB

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

http://www.wikidata.org/entity/Q34524946

about

Sphingosine-1-Phosphate Metabolism and Its Role in the Development of Inflammatory Bowel Disease Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Sphingosine 1-Phosphate Receptor Modulators and Drug Discovery.Race/Ethnicity-Specific Disparities in the Severity of Disease at Presentation in Adults with Ulcerative Colitis: A Cross-Sectional Study.Treating children with inflammatory bowel disease: Current and new perspectives.Medical versus surgical management of penetrating Crohn's disease: the current situation and future perspectives.New treatment strategies for ulcerative colitis.Current and Future Targets for Mucosal Healing in Inflammatory Bowel Disease.Disease activity and mucosal healing in inflammatory bowel disease: a new role for histopathology?The safety of non-biological treatments in Ulcerative Colitis.Novel Insights into the Mechanisms of Gut Homing and Antiadhesion Therapies in Inflammatory Bowel Diseases.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.Lessons Learned From Trials Targeting Cytokine Pathways in Patients With Inflammatory Bowel Diseases.The Present and Future of Inflammatory Bowel Disease Treatment.Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway: Therapeutic Targets in Autoimmunity and Inflammation.Adalimumab in ulcerative colitis - efficacy, safety and optimization in the era of treat-to target.Next-Generation Therapeutics for Inflammatory Bowel Disease.Therapeutic Strategies and Pharmacological Tools Influencing S1P Signaling and Metabolism.Update on the Use of Biologic Therapy in Ulcerative Colitis.Sphingosine 1-Phosphate Receptor 1 Signaling in Mammalian Cells.Frontiers in Drug Research and Development for Inflammatory Bowel Disease.Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator.Antibiotics promote the sampling of luminal antigens and bacteria via colonic goblet cell associated antigen passages.Emerging oral targeted therapies in inflammatory bowel diseases: opportunities and challenges The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.Sphingolipids and their metabolism in physiology and disease.Novel treatments for inflammatory bowel disease.Targeting S1P in Inflammatory bowel disease: new avenues for modulating intestinal leukocyte migration.Placebo response and remission rates in randomised trials of induction and maintenance therapy for ulcerative colitis.Immunological pathogenesis of inflammatory bowel disease.Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.Precision Medicine in Inflammatory Bowel Diseases.New treatment options for inflammatory bowel diseases.Ozanimod (RPC1063), a selective S1PR1 and S1PR5 modulator, reduces chronic inflammation and alleviates kidney pathology in murine systemic lupus erythematosus.Next generation of small molecules in inflammatory bowel disease.Improving IBD Care: A Personalized Approach to Management.

P2860

Q30235011-E53F80E7-F3E4-4567-B440-7CFBF3FD0E56 Q30248641-5BB2493F-50F3-4237-91D1-5AFB89CF0502 Q37551932-20D5D0EF-AA45-4C5B-BD04-E38971A5D7B3 Q38601056-F86DA58F-F9D7-4206-A5A9-0657C7F9D8B8 Q38602911-A5CBE3C1-C73C-416A-BB4E-0CABF37181B2 Q38668874-90CDAE7B-70EC-4609-A2D2-AEE4CDD53E0E Q38670811-B1776D05-B40D-4909-8EC0-8B0381EF99A3 Q38671272-78E34623-3D8A-40A7-8469-18DC10BB85ED Q38677581-9A819C3D-7CC8-4F6C-9269-2549B28A9CB9 Q38728164-1DC7E47C-35D5-43DF-A27B-478BE7951EE7 Q38744708-544FB74F-5D74-4CF7-BD0F-1E5FB232BB26 Q38761961-E35F66F7-4D7E-42A9-82FC-8ABC9730A8CD Q38795652-0571578E-055C-420A-989D-1022499E74DA Q38805575-1D4AAF25-B058-4515-973B-9ABC3207A3ED Q38834699-DAD2F74B-F047-4940-A675-2406E1309E02 Q38869471-F7555ABD-E688-4012-8BF0-A75A202306F8 Q38895960-5C2E05F5-8C43-4AE0-92A4-CF5C8DA7F60D Q38909523-7CCA29CF-D09C-4AAD-A5E7-C8307A1B7889 Q38915115-D2A9FC35-B5DF-4326-B147-CF3C7893DD8C Q39102244-46C8E6F9-35E9-44A7-99C3-C35144AF8265 Q39152899-5FE7C80A-6508-46A1-B473-4EF98305669C Q39424463-F7F41F7A-C96F-4D8C-9FF6-391105C49373 Q41052913-0F52A1EB-589D-4447-8F18-C8E1D40C7921 Q41513942-F51D4FF6-9C17-4E87-8977-FF6F9D2FE4FE Q42375646-1A0229C4-637C-421D-B116-9E71BC6099AB Q44581309-8AC2C09F-30CE-44EC-BC4E-294DB07C5D84 Q46025818-8DC901DF-FDC7-4A71-95AB-02D41ABC6E6F Q46572613-BB7AB592-D445-4F54-9CEB-36B8D3E01E98 Q47109861-258BED46-067E-47CA-BA09-EB62B935A84E Q47374235-62AE4E4A-A742-40CB-A2A3-8BF0C57E123B Q47563211-87E7C26D-C969-4685-BDED-0606B4C8A5F9 Q47725521-1D3E5604-6212-41FD-83F4-4F040BB5BCA9 Q47958039-27D54659-1703-4CDE-B1D3-90782EB26BC9 Q50042967-437EBDD1-D86F-427A-ADFB-E4F0ED317ED9 Q50070747-87F95E0E-44C7-4C24-8B0E-2C512EF0820D Q51828636-365036F8-AFAC-4EFE-B063-4D31C570E843 Q52647462-2A08D6A2-F88B-4157-B08B-279F4BA385D1 Q54935877-C83B1FA5-DFF1-42C0-95BB-27966ED75B5C Q55007993-561A3052-EC95-40BB-8CE2-54D9231A8114 Q55512056-879AD8AF-970E-4B90-96A8-34664F6B8754

P2860

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

http://www.wikidata.org/entity/Q34524946

description

2016 nî lūn-bûn

@nan

2016 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@ast

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@en

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@nl

type

label

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@ast

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@en

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@nl

prefLabel

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@ast

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@en

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@nl

P1433

Q34524946-E67A5155-B019-42CB-8365-A2614180BA43

P1476

Q34524946-1915959E-7C68-4AA7-8C9C-24886266BCCF

P2093

Q34524946-4214B59C-343E-44CF-9A62-131D0DDFC4E1

Q34524946-496382E1-7B0C-4B1A-9B76-456E565A97D9

Q34524946-5E1B18AE-4217-4ED9-B119-96ECFD7BD19A

Q34524946-88624379-FD4D-4029-B79B-72A759464283

Q34524946-8BF9056D-D84A-44FC-AF18-A18A00E7707A

Q34524946-AB8380B8-6DDE-4A66-A64C-66D0CA2FE098

Q34524946-E7F558C0-F495-455D-92F5-19FF192E9A70

Q34524946-EDD963AF-1346-436F-BC8D-C67086138E3C

Q34524946-F354E270-958B-4260-9B59-FE3E66BCF88D

Q34524946-F6165A56-7AD5-4587-83F6-A66CF9020951

P304

Q34524946-2D9729A3-02A3-48CA-85DB-7EDE28D8BC96

P31

Q34524946-3379BE3D-0EF7-4490-844A-808A3D0BB494

P356

Q34524946-576F3A05-7D4F-475C-9FF1-B3E738CBDE6D

P407

Q34524946-4A39651D-FD07-46DD-B6EB-BF5EF22B22BC

P433

Q34524946-94F54F5A-DA7C-45AF-A4DF-984FBCFFCDB6

P478

Q34524946-6C768266-7D8C-460A-9CE9-57BB99D30E27

P50

Q34524946-4275B2EC-E299-4271-9EE6-49179AC19BF7

Q34524946-6E37C91B-2B29-4253-8606-596099DDC016

Q34524946-A39C513E-E263-4FEC-8E5B-1D13672683EA

P577

Q34524946-A2037797-D0A1-4FED-B7F9-6B0075B73277

P698

Q34524946-F496C659-CF18-4797-B362-C39701F3EA3E

P356

P1433

The New England Journal of Medicine

P1476

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis.

@en

P2093

Allan Olson

http://www.w3.org/2001/XMLSchema#string

Douglas C Wolf

http://www.w3.org/2001/XMLSchema#string

Heather Smith

http://www.w3.org/2001/XMLSchema#string

Matthew Cravets

http://www.w3.org/2001/XMLSchema#string

Paul A Frohna

http://www.w3.org/2001/XMLSchema#string

Richard Aranda

http://www.w3.org/2001/XMLSchema#string

Severine Vermeire

http://www.w3.org/2001/XMLSchema#string

Sheila Gujrathi

http://www.w3.org/2001/XMLSchema#string

Stephen B Hanauer

http://www.w3.org/2001/XMLSchema#string

Subrata Ghosh

http://www.w3.org/2001/XMLSchema#string

P304

1754-1762

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1513248

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

Brian G. Feagan

P577

2016-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27144850

http://www.w3.org/2001/XMLSchema#string